Mersana Therapeutics, Inc.
MRSN
$7.65
-$0.10-1.29%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 10.97% | -83.17% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 10.97% | -83.17% | |||
| Cost of Revenue | -11.58% | -17.70% | |||
| Gross Profit | 15.56% | -163.07% | |||
| SG&A Expenses | -16.92% | 0.44% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -13.32% | -12.53% | |||
| Operating Income | 16.05% | -65.50% | |||
| Income Before Tax | -0.72% | -70.88% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -0.72% | -70.88% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -0.72% | -70.88% | |||
| EBIT | 16.05% | -65.50% | |||
| EBITDA | 16.14% | -67.90% | |||
| EPS Basic | -0.55% | -69.64% | |||
| Normalized Basic EPS | 15.75% | -69.63% | |||
| EPS Diluted | -0.55% | -69.64% | |||
| Normalized Diluted EPS | 15.75% | -69.63% | |||
| Average Basic Shares Outstanding | 0.16% | 0.73% | |||
| Average Diluted Shares Outstanding | 0.16% | 0.73% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||